Astrazeneca PLC Press Releases

AZN 
$33.94
*  
0.15
0.44%
Get AZN Alerts
*Delayed - data as of Aug. 3, 2015  -  Find a broker to begin trading AZN now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    AZN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By













CORRECTING and REPLACING IRESSA® (gefitinib) Approved by the U.S. Food and Drug Administration for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer
7/13/2015 7:27:00 PM - Business Wire
▼-49.48 % Price Change since this news event. The Volume Ratio is 0.73.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


IRESSA® (gefitinib) Approved by the U.S. Food and Drug Administration for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer
7/13/2015 7:27:00 PM - Business Wire
▼-49.48 % Price Change since this news event. The Volume Ratio is 0.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AstraZeneca Celebrates More Than 35 Years of Ongoing Patient Support Through Its Patient Assistance Programs
7/8/2015 8:00:00 AM - Business Wire
▼-47.36 % Price Change since this news event. The Volume Ratio is 0.72.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AstraZeneca Announces Phase III Results for Lesinurad in Combination with Febuxostat in Tophaceous Gout Patients at European League Against Rheumatism Annual Congress (EULAR 2015)
6/13/2015 9:00:00 AM - Business Wire
▼-48.33 % Price Change since this news event. The Volume Ratio is 0.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Cholesterol Awareness Initiative Makes Its Move Across America
6/8/2015 9:24:00 AM - PR Newswire
▼-48.99 % Price Change since this news event. The Volume Ratio is 0.96.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






AstraZeneca Updates on Immuno-Oncology Combinations Development Program at ASCO 2015
6/2/2015 9:27:00 AM - Business Wire
▼-49.17 % Price Change since this news event. The Volume Ratio is 0.73.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AstraZeneca Presents Positive Data on AZD9291 in First-Line EGFR Mutated Lung Cancer at ASCO 2015
5/31/2015 9:00:00 AM - Business Wire
▼-49.76 % Price Change since this news event. The Volume Ratio is 1.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AstraZeneca and MedImmune Present Positive Immuno-Oncology Combination Data at ASCO 2015
5/30/2015 9:28:00 AM - Business Wire
▼-49.76 % Price Change since this news event. The Volume Ratio is 1.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day








Olympic Gold Medalist Jackie Joyner-Kersee Teams up with AstraZeneca to Raise Awareness about Opioid-Induced Constipation
5/20/2015 9:00:00 AM - Business Wire
▼-50.28 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day